Supplementary Figure 3 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.

What problem does this paper attempt to address?

Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039.v1

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.
Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036.v1

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure S1 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461797.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining results of immunohistochemistry.
Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461794

2023-01-01

Abstract:Supplementary Figure S2. Overall survival of melanoma patients in relation to mTOR nonsynonymous mutations.
Supplementary Figure 1 from Detection and Dynamic Changes of egfr Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok,Yi‐Long Wu,Jin Soo Lee,Chong‐Jen Yu,Virote Sriuranpong,Jennifer Sandoval-Tan,Guia Ladrera,Sumitra Thongprasert,Vichien Srimuninnimit,Meilin Liao,Yunzhong Zhu,Caicun Zhou,Fatima Fuerte,Benjamin Margono,Wen Wang,Julie H. Tsai,Matt Truman,Barbara Klughammer,David S. Shames,Wenxiong Lin

DOI: https://doi.org/10.1158/1078-0432.22459443.v1

2023-01-01

Abstract:Supplementary Figure 1. (A) PFS in the cfDNA mut+ subgroup (B) OS in the cfDNA mut+ subgroup (C) PFS in the cfDNA mut+ subgroup (patients with no tissue result) (D) OS in the cfDNA mut+ subgroup (patients with no tissue result) (E) PFS in the cfDNA mut- subgroup (F) OS in the cfDNA mut- subgroup (G) PFS in the cfDNA mut- subgroup (no tissue result )(H) OS in the cfDNA mut- subgroup (no tissue result)
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Figure 1 from Lung Cancers with Concomitant egfr Mutations and alk Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Jin-Ji Yang,Xu-Chao Zhang,Jian Su,Chong-Rui Xu,Qing Zhou,Hong-Xia Tian,Zhi Xie,Hua-Jun Chen,Yi-Sheng Huang,Ben-Yuan Jiang,Zhen Wang,Bin-Chao Wang,Xue-Ning Yang,Wen-Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Tony S. Mok,Yi-Long Wu

DOI: https://doi.org/10.1158/1078-0432.22448817.v1

2023-01-01

Abstract:PDF file - 635KB, Sequence results of EML4-ALK fusion variants.
Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2
Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461795

2023-01-01

Abstract:Kaplan-Meier survival curves for relapse free and overall survival according to EGFR, KRAS, BRAF, HER2, FGFR or wild-type status
Supplementary Figure 4 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators bap1 and setd2: A Report by MSKCC and the KIRC TCGA Research Network

A. Ari Hakimi,Irina Ostrovnaya,Boris Reva,Nikolaus Schultz,Ying-Bei Chen,Mithat Gönen,Han Liu,Shugaku Takeda,Martin H. Voss,Satish K. Tickoo,Victor E. Reuter,Paul Russo,Emily H. Cheng,Chris Sander,Robert J. Motzer,James J. Hsieh

DOI: https://doi.org/10.1158/1078-0432.22447230.v1

2023-01-01

Abstract:PDF File - 111K, TCGA mutation combination cancer specific survival curves.
Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396160

2023-01-01

Abstract:PDF file - 407K, DNA damage induced by BRAFV600E in human melanoma cells.
Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396163

2023-01-01

Abstract:PDF file - 343K, p53 function in BRAFV600E/ARF-/- murine melanoma cells.
Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Y. Kong,L. Si,J. Guo,Z. H. Chi,C. L. Cui,X. N. Sheng,B. X. Tang

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8568

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:8568 Background: Mutations in KIT, BRAF, NRAS and PDGFRA are common in melanoma, which have not been extensively studied in Asia. We examined these aberrations and correlated the aberrations to the clinical features and survival in Asian melanoma patients. Methods: This study involved samples from 644 melanoma patients in Peking University Cancer Hospital. Clinical data were collected. Tissue samples were analyzed for mutations in KIT (exons 9,11,13,17,18), BRAF (exons 11,15), NRAS (exons1,2) and PDGFRA (exons 12,14,18) genes by PCR amplification and Sanger sequencing. The copy numbers of KIT gene were analyzed by quantitative PCR. Results: The incidence of somatic mutations within the KIT, BRAF, NRAS and PDGFRA genes was 10.1% (58/573), 25.9% (121/468), 7.2% (33/459) and 4.8% (17/352), respectively. The incidence of increased KIT copy number was 7.6% (39/516). The highest KIT mutation frequency is within the CSD subgroup (27.3%, 9/33). Increased KIT gene copy number was comparatively more frequent in acral (8.0%, 14/176) and mucosal (11.5%, 17/148) melanomas than in CSD (3.2%, 1/31) and Non-CSD (1.9%, 2/104) melanomas. Surprisingly, BRAF mutations were detected in 17.9% (28/156) of acral melanomas and 12.5% (16/128) of mucosal melanomas. The most frequent mutation in BRAF was V600E (87.3%). The median follow-up period was 24 (3~229) months (n=473). No statistical differences were found for thickness and ulceration rates between melanomas with or without these mutations (P=0.6). The median survival for patients with KIT mutations (30 months) and BRAF (33m) were significantly shorter than for patients with WT tumors (53m; P=0.01, P=0.005 respectively). Overall survivals were similar in groups with or without NRAS and PDGFRA mutations. Conclusions: KIT and BRAF are important oncogenes in Asian melanomas. Mutations in the BRAF gene were more common than KIT mutations. For the first time, our study suggests that genetic KIT and BRAF aberration is an adverse prognostic factor for melanoma. These results suggest that the KIT inhibitor as well as BRAF V600E inhibitor might play their roles in Asian melanoma patients. Supported by the National Natural Science Foundation of China30973483.
Supplementary Figure 5 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Lanlan Pang,Yihua Huang,Weitao Zhuang,Yaxiong Zhang,Jun Liao,Yue Hao,Feng Hao,Guoqian Wang,Ze-xin Chase Chen,Yu Zhu,Mengzhen Li,Zhengbo Song,Bo Peng Deng,Jing Li,Li Zhang,Wenfeng Fang

DOI: https://doi.org/10.1158/1078-0432.26037486.v1

2024-01-01

Abstract:Supplementary Figure 5. Structural modeling of EGFR p.G719A/E709K in a complex with afatinib.
Supplementary Figure 2 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Lanlan Pang,Yihua Huang,Weitao Zhuang,Yaxiong Zhang,Jun Liao,Yue Hao,Feng Hao,Guoqian Wang,Ze-xin Chase Chen,Yu Zhu,Mengzhen Li,Zhengbo Song,Bo Peng Deng,Jing Li,Li Zhang,Wenfeng Fang

DOI: https://doi.org/10.1158/1078-0432.26037495

2024-01-01

Abstract:Supplementary Figure 2. Impact of EGFR p.E709X mutation in patients harboring EGFR p.G719X mutant patients and genomic features of EGFR p.G719X mutant patients with NSCLC in the validation cohort.
Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong,Xinan Sheng,Xianliang Wu,Junya Yan,Meng Ma,Jihong Yu,Lu Si,Zhihong Chen,Chuanliang Cui,Jie Dai,Yiqian Li,Huan Yu,Teng Xu,Huan Tang,Bixia Tang,Lili Mao,Bin Lian,Xuan Wang,Xieqiao Yan,Siming Li,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22463072.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining of CDK4 pathway-related proteins Supplementary Figure S2. Sensitivity of acral melanoma cells to CDK4/6 inhibitors. Supplementary Figure S3. Western blotting assays of total Rb and phosphorylated Rb (pRb) in cell lines after CDK4/6 inhibitor treatments Supplementary Figure S4. Representative images of tumor nodules after the treatments. Supplementary Figure S5. Rb inactivation status in PDX models after AT7519 and PD0332991 treatments.
Supplementary Figure 3 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Lanlan Pang,Yihua Huang,Weitao Zhuang,Yaxiong Zhang,Jun Liao,Yue Hao,Feng Hao,Guoqian Wang,Ze-xin Chase Chen,Yu Zhu,Mengzhen Li,Zhengbo Song,Pengbo Deng,Jing Li,Li Zhang,Wenfeng Fang

DOI: https://doi.org/10.1158/1078-0432.26037492.v1

2024-01-01

Abstract:Supplementary Figure 3. Genomic characteristics was found between patients receiving afatinib or the third-generation EGFR-TKIs.
Supplementary Figure 1 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Lanlan Pang,Yihua Huang,Weitao Zhuang,Yaxiong Zhang,Jun Liao,Yue Hao,Feng Hao,Guoqian Wang,Ze-xin Chase Chen,Yu Zhu,Mengzhen Li,Zhengbo Song,Pengbo Deng,Jing Li,Li Zhang,Wenfeng Fang

DOI: https://doi.org/10.1158/1078-0432.26037501.v1

2024-01-01

Abstract:Supplementary Figure 1. Study design.

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 1 from Detection and Dynamic Changes of <i>egfr</i> Mutations from Circulating Tumor DNA As a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 1 from Lung Cancers with Concomitant <i>egfr</i> Mutations and <i>alk</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Figure 4 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Supplementary Figure 5 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Figure 2 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Supplementary Figure 3 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Figure 1 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Figure 3 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib